Best Penny Stocks 🚀 to buy and watch in May 2020 NASDAQ:CLVS
😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks
FDA date of approval - 15.05.2020
Our Strategy with this Stock :
This company provides prostate cancer therapy . And as you can see there is huge previous spikeability in the company regarding their previous drug in their pipelines . It's going to be the first targeted therapy for prostate cancer Which alone brings a lot of news attention to the analysts already but the average price for the stock to $20 , which is my personal opinion I think it's very far from reality. I'm looking for a price of about 15 to $16 Max !!!
I put my alarm at 9.6$ . to monitor any anticipatory run up
What’s the real story :
The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply .
How can you actually use this ?
We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨🎓.
The Best Part
You can follow me and apply my trades for FREE !!!
QUESTIONS ?
Please comment below , what you have in mind 😊
Pharmaceutical
Palatin Technologies (PTN) Breakout, retest, potential triple bottom
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.
PFIZER looking for a bullish move towards the 40 area . NYSE:PFE looks to be heading up towards the 40 area very soon .
NAVAMEDIC (NAVA) | Perfect Technically but Fundamentally So-So!Hi,
Navamedic ASA, a MedTech and pharmaceutical company, in-licenses, buys and markets pharmaceuticals and other health care products in the Northern European region.
Considering technical viewpoints then Navamedic has started to approach a pretty strong support area, a lot of criteria make up a strong crossing area. To be honest, I don't know much about Navamedic fundamentals but I can say, if you see some perspective in the future then this would be your perfect spot to buy it if you don't see then SKIP IT!!
Technically a strong support area/buy-zone consists of:
1) A very strong resistance level becomes support. The price tried to break above the lower orange line 9(!) years and in the last year, it finally was successful. Now, this very strong resistance should act as a support level.
2) Inside the green buy-zone are also Monthly EMA50 and EMA100, plus Weekly EMA200 - all of them should act as support levels.
3) Fibonacci Golden ratio - Fibo retracement 62%
4) Navamedic becomes a member of a 50% club if the price reaches into the marked area.
5) Weekly timeframe AB=CD
6) Weekly timeframe channel projection
It should be a pretty good spot to gain short-term profits, a perfect area should stay between 11.00-12.50
As said, do your own fundamental research and if this matching with my technical analysis viewpoints then you are ready to go! If it doesn't match then...skip it!!
Regards,
Vaido
Merck: Ichimoku Clouds on bullish setupIchimoku Clouds still confirm the bullish setup. Today's session will be important, if positive, to manifest further bullish intentions (Break of the $92.10 resistance).
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
Alexion: Today's opening is confirming the bullish assumptionGood spot for Alexion Pharmaceuticals. The stock is trading above the Ichimoku Cloud Support (red line of the green cloud).
I was waiting for today's opening to confirm a bullish position.
Furthermore, Alexion trades below its normal Price/Ebitda ratio of 41.13 (currently trading at 11.89).
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
Biogen: Further GrowthAfter the stock price touched new highs in October 2019 ( management confirmed rebooting of aducanumab's development), Biogen started a consolidation phase.
I plotted the Ichimoku Cloud on a daily chart, together with the Bollinger bands, to highlight the volatility and confirm the consolidation phase. Currently, from a technical point of view, we are in an exciting phase, testing the high line of the cloud with a bullish configuration, as also confirmed by the Stochastic.
The upward trend is also confirmed by fundamental analysis. Biogen counts on a strong collaboration with Roche in oncology, and on growing revenues thanks to Ocrevus (Multiple Sclerosis), as well as to a significant pipeline.
Furthermore, the complexity of Biogen's drugs makes the production of Biosimilars difficult.
Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
VSTM - Bear Trend ReversalBear Trend Reversal - Long term downtrend rejected with bullish RSI divergence on the weekly.
These hops off a long-term bear trend reversals can be swift and powerful. I've played these before and won (DAN...TQQQ after '18 Christmas)..but I've also played these and lost (MAXR).
I've previously played these directly on the instrument, but this time I'm playing this with 10 buys of $2 March 20, 2020 calls. Hoping to see a continued surge of implied volatility for these options as I don't plan on holding them through expiry. That being said, I've yet to really win on any of my options trades...but IV is on the up and up since my purchase so we'll just have to wait'n'see.
LA JOLLA PHARMACEUTICAL CO - NASDAQ: $LJPC Requires Your Eyes After breaking to higher ground back in June on large volume, shares of LA JOLLA PHARMACEUTICAL CO - NASDAQ:LJPC have been drifting in a sideways pattern consolidating the move in a constructive manner as we can observe from the Daily chart above.
With the stock trading above all of its important moving averages 20/50/200 DMA's, LJPC remains in decent technical shape, albeit, a bit of work remains.
Thus, both investors/traders may want to continue to monitor the action in LJPC moving forward and more specifically, should the stock be capable of going topside of the $10.90 figure and can 'stick', such scenario, should it develop, would likely signal/trigger its next meaningful advance with and initial objective of $14 and a secondary objective in the $16 area.
Nonetheless, LJPC continues to display fairly decent action and both investors/traders may want to put the shares front-and-center on their radars awaiting further clues/evidence that things may be about to pick-up.
Bear Trend Reversal - ACRXACRX - Long
Seems a bit range bound and put in a nice bottom on the long trend line. Blew by the 8EMA and 20SMA and closed over the 50SMA after a blip below 30RSI at the lower part of the range. Big risk trade given the low price and rangy price action. SL set at 1.5xATR which is just below the long-term bottom of the range.
ACRX - 500 Shares
Entry - $2.71
SL - $2.17
TP - $3.81
Net Risk - $270
(Note: as of this post looks like we're well up in pre-market)
Smells Like a PumperBreakout about the 100 day VWMA and CCI is crawling out of the hole, another rush upwards is in the works. To what point is anyone's guess. Personally not going to buy in unless it has a nice pullback toward the 2.00 level.
Best to play this like anything else - with patience and discipline.
Novartis Pharma going up on MACDNVS Novartis owns or makes a slew of pharmacopial needs for a variety of medical needs.
Little dip during recent pullback.
Watching Friday ads, all brand names no companies. All Novartis or made for another company by Novartis.
Bespoke - Billionaire pumped CBD stock watchBespoke is a CBD Oil from HEMP stock with all the dressings to grow, but was bubble busted over the past few weeks. Watching to buy only when 1) MACD crosses 0 and 2) CCI going into upward buy point (see earlier circled period ), or see area's for shorting. This stock simply was overvalued, oversold, and over-pumped by billionaire hoping to get rich pumping newsletter to pushit, oh 2 words eh?? Would love to hear from anyone who has Bespoke as short-long investment, okay to rant here briefly if long.
I can not emphasize the value of CBD oil and such stock will have to reduce opioid and pain meds as first wooded box stand comment. Thus my preferred watch is CVSI , GWPH , CBDS , CRBP , PMCB , ,and CARA. BSPK
CBD Oil from HEMP is more profitable than from Cannabis as #2.
Third is that HEMP can contain trace THC, but is below 0.3% and often removed with waxes in most distallation processes by alcohol, albeit expensive.
Which HEMP is legal in all 50 states and all of No. America and Europe, why HEMP was made illegal before if like taxing money that smells like it's been taxed before, dumb.
This is for watching only, so follow, like and share if you follow this sector with @pokethebear. @MarxBabu for longbuylongsell (buy on blue 4h/1d, sell on black charting. @Tradingviewpoints
MYL first signs of strenght for Mylan nice occasionsin the chart I highlighted the last bounce from the "hystorical support" at 35,40 dollars. I drew also the main downtrend line since 12/2015. This is an interesting point because 2 solid supports pass thorugh it and price is conferming this bullish area. Earnings are expected to come in two weeks but in any case this is a tempting occasion to go long with tight SL slighlty under 35,40 dollars.
ATNX to retest Support high 17's to mid 18'sATNX may be a tad over extended for now and will likely retrace to it's 18.50 or high 17's support area. May look for a buy in here. ANTX recently named Timothy Cook as senior vice president of global commercial oncology. This is recent add to an all star team in the oncology pharma space. I see a bright future for this asset.
***Any information represented here is my opinion only and not intended to be used for financial gain. None of the information posted here is to be considered financial advice. Information posted here is strictly for entertainment purposes only. Please consult your financial professional before making any kind of investment. Investments can be very risky and any investor should educate themselves before investing by enlisting the help of a financial professional. Past results are not indicative of future results in any construable way.***
SNDX - Syndax Pharmaceuticals - Loyal to the base bounce?First of all, I'm in love with this chart, not like a friend, but like a secret admirer whilst in high school going thru my hormonal changes. Syndax Pharmaceuticals has consistently shown great loyalty to the bounce when it reaches lower levels, close to or under it's support. This Pharma stock has shown to have great support at about $8.00. SNDX has a couple products out right now that are in testing phases, Entinostat and the SNDX-6352. The recent 25% decline was due to the Phase 2 of the study being "unimpressive". This trial however, serves as a base for positive results for phase 3 trials, which is coming up soon. We should see some consolidation at this level until the results are provided, then a possible jump. Make sure you take profits!! We're looking at a target price on the low end of $12.00, and as high as $18.00. SNDX is currently sitting at $7.03 as I'm writing this.
Small Pharma Big Backers and Partners - LONG SNG (Synairgen)Prudent Drug Discovery Company
Low market cap ( appox £13m at time of writing ).
Issues shares very rarely ( last placing nearly four years ago ).
Has material interest in its work from larger partners ( Pharmaxis ).
Sold interest in LOXL2 programme for £5m to Pharmaxis in December.
Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains interest across all fibrotic indications at circa 17% of all partnering proceeds.
Potential of drug appears across multiple uses now ( not just lung-related ) and indications from Pharmaxis looking very good.
Recent interviews from Pharmaxis management suggest a good chance of a deal with major pharma in H2.
Low free float in the stock ( 60% in hands of major shareholders ).
Major funds holding ( Woodford Investment Management and Lansdowne Partners ).
High profile investors holding stakes ( Richard Griffiths and Leonard Licht ).
These high profile investors have been raising, rather than reducing their stakes in the company, periodically.
For a risky smallcap biotech stock it appears well placed to survive and thrive, regardless of the short term success of a sale/licencing deal of LOXL2 by Pharmaxis, making it considerably less risky than most biotech stocks in the long term. However, the indications and noises being made about LOXL2 by Pharmaxis are looking as positive as you could hope for, and backed up by them putting their money where their mouth is in the first place and increasing their stake for cash.
Arrowhead Pharmaceuticals Massive Institutional AccumulationStock tanked last year because hep b trials killed a chimp, so they shelved project to focus on Amgen and RNAi program therapies.
Buy half now, buy the other half on a pullback. Fucking beautiful chart. BEAUTIFUL
Only short to medium term risk is dilution, which is a very real possibility . The buying is just SO strong though, wow. BEAUTIFUL, like, it's ....just,.....its a beautiful chart. So firm and consistent, and green, with heavy volume. For it to have responded so strongly after a major investor left is very indicative of positive outcomes in the future.
Late 2016
-Amgen to Receive Worldwide Exclusive License to Arrowhead's RNAi ARC-LPA Program
-Amgen Receives Exclusive License Option to RNAi Therapy for Undisclosed Cardiovascular Target
-Arrowhead to Receive $56.5 Million in Upfront Payments and Initial Equity Investment and up to an Additional $617 Million in ------Potential Milestone and Equity Payments
up to $617 million in option payments, and development, regulatory and sales milestone payments
"Arrowhead's expertise in RNAi makes them a valuable partner as we translate genetic discoveries into potential therapies that can improve health outcomes for patients," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "This collaboration builds upon our commitment to cardiovascular disease with targets that we believe are uniquely suited for RNAi-based therapy."
"We have made great advances to our proprietary subcutaneous RNAi delivery vehicle and in RNAi trigger modification and stabilization that enable rapid development of new RNAi therapeutics across multiple disease areas," said Christopher Anzalone, Ph.D., president and chief executive officer at Arrowhead. "Our capabilities and platform technologies are becoming increasingly validated, so we feel that now is a great time to expand the reach of our technologies and partner with other companies to maximize the value of our assets. We are thrilled to be working with Amgen, one of the world's leading biotechnology companies, on this collaboration. Amgen's extensive development, regulatory, and commercial expertise makes them an ideal partner, and we look forward to a long and productive relationship."
$AITB - AIT Therapeutics Inc - Buy AlertAIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and for nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com
Tandem Diabetes Care Looks Like a Good Daytrade, SwingTrade PlayStock price has not been fully established yet. Lots of uncertainty, meaning lots of opportunity for short term fluctuations. Stock just underwent reverse split. Currently a "low floater", but with real business operations, not just some cheap pump and dump scam from china or some bitcoin stock. Its a real company with real aspirations of survival. Only problem is they have much better established industry peers like Medtronics. They are still considered a player in their respective industry. Keep on watchlist, watch for movement interday, and if opportunity presents, play it.
Reason for watching, low float, recent split, and real company which is a rare thing these days in the stock market it seems like, especially if it has a low float and a real product. No MACD here people, lol. With these risky ones, flat line is a good thing after a big sell off after a reverse split, especially in a bull market. once the sellers are clearly out of the way, that's all you need to know when the stock has a low float, recent reverse split, and healthy trading volume
$ARNA, $1.50 on the menu... Again!Stock insanely undervalued with Belviq and a great board! Biotechs tend to perform well in bear markets.
I will create a google drive for company models, so that everyone has access.
1.50 is a great price to buy more if you are already in this
GL
www.tradingsignalreviews.com
